Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study

Jinyoung Kim; Kyungdo Han; Bongsung Kim; Ki Hyun Baek; Ki Ho Song; Mee Kyoung Kim; Hyuk Sang Kwon

doi:10.1016/j.diabres.2022.110187

Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study

Jinyoung Kim, Kyungdo Han, Bongsung Kim, Ki Hyun Baek, Ki Ho Song, Mee Kyoung Kim, Hyuk Sang Kwon

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Aims: This study was to determine the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes. Methods: We used data from the Korean National Health Insurance Service from 2014 to 2017. New drug users were screened, dipeptidyl peptidase 4 inhibitors (DPP4i) were set as the active comparator, and the differences between the two groups were corrected through propensity score matching. NAFLD was evaluated by the fatty liver index (FLI), which was calculated using body mass index, waist circumference, triglycerides, and gamma glutamyl peptidase. Results: After 1:1 matching, 25,371 patients in each group who received medication for an average of 299 days were analyzed. Despite similar baseline FLI of each group, the FLI of the SGLT2i users was 44.4 ± 26.7 and the FLI of the DPP4i users was 48.9 ± 27.3 (P value < 0.001) after treatment. SGLT2i showed more significant decrements than DPP4i in all components of FLI. The more the adherence to the SGLT2i increased, the greater the decrease in FLI. Conclusions: SGLT2i showed a significant reduction in FLI and its components. We suggest that SGLT2i may have beneficial effects in reducing the prevalence of NAFLD in type 2 diabetes.

Original language	English
Article number	110187
Journal	Diabetes Research and Clinical Practice
Volume	194
DOIs	https://doi.org/10.1016/j.diabres.2022.110187
State	Published - Dec 2022

Bibliographical note

Funding Information:
The authors would like to thank the Korean National Health Insurance Service for cooperation.

Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2021R1A2C2013890).

Publisher Copyright:
© 2022 Elsevier B.V.

Keywords

Dipeptidyl peptidase 4 inhibitors
Nonalcoholic fatty liver disease
Sodium-glucose cotransporter 2 inhibitors
Type 2 diabetes mellitus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diabres.2022.110187

Cite this

@article{1d90b155f51a4feb8cf35d1ba4e47b11,

title = "Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study",

abstract = "Aims: This study was to determine the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes. Methods: We used data from the Korean National Health Insurance Service from 2014 to 2017. New drug users were screened, dipeptidyl peptidase 4 inhibitors (DPP4i) were set as the active comparator, and the differences between the two groups were corrected through propensity score matching. NAFLD was evaluated by the fatty liver index (FLI), which was calculated using body mass index, waist circumference, triglycerides, and gamma glutamyl peptidase. Results: After 1:1 matching, 25,371 patients in each group who received medication for an average of 299 days were analyzed. Despite similar baseline FLI of each group, the FLI of the SGLT2i users was 44.4 ± 26.7 and the FLI of the DPP4i users was 48.9 ± 27.3 (P value < 0.001) after treatment. SGLT2i showed more significant decrements than DPP4i in all components of FLI. The more the adherence to the SGLT2i increased, the greater the decrease in FLI. Conclusions: SGLT2i showed a significant reduction in FLI and its components. We suggest that SGLT2i may have beneficial effects in reducing the prevalence of NAFLD in type 2 diabetes.",

keywords = "Dipeptidyl peptidase 4 inhibitors, Nonalcoholic fatty liver disease, Sodium-glucose cotransporter 2 inhibitors, Type 2 diabetes mellitus",

author = "Jinyoung Kim and Kyungdo Han and Bongsung Kim and Baek, {Ki Hyun} and Song, {Ki Ho} and Kim, {Mee Kyoung} and Kwon, {Hyuk Sang}",

note = "Funding Information: The authors would like to thank the Korean National Health Insurance Service for cooperation. Funding Information: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2021R1A2C2013890). Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",

year = "2022",

month = dec,

doi = "10.1016/j.diabres.2022.110187",

language = "English",

volume = "194",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus

T2 - A nationwide propensity-score matched cohort study

AU - Kim, Jinyoung

AU - Han, Kyungdo

AU - Kim, Bongsung

AU - Baek, Ki Hyun

AU - Song, Ki Ho

AU - Kim, Mee Kyoung

AU - Kwon, Hyuk Sang

N1 - Funding Information: The authors would like to thank the Korean National Health Insurance Service for cooperation. Funding Information: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2021R1A2C2013890). Publisher Copyright: © 2022 Elsevier B.V.

PY - 2022/12

Y1 - 2022/12

N2 - Aims: This study was to determine the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes. Methods: We used data from the Korean National Health Insurance Service from 2014 to 2017. New drug users were screened, dipeptidyl peptidase 4 inhibitors (DPP4i) were set as the active comparator, and the differences between the two groups were corrected through propensity score matching. NAFLD was evaluated by the fatty liver index (FLI), which was calculated using body mass index, waist circumference, triglycerides, and gamma glutamyl peptidase. Results: After 1:1 matching, 25,371 patients in each group who received medication for an average of 299 days were analyzed. Despite similar baseline FLI of each group, the FLI of the SGLT2i users was 44.4 ± 26.7 and the FLI of the DPP4i users was 48.9 ± 27.3 (P value < 0.001) after treatment. SGLT2i showed more significant decrements than DPP4i in all components of FLI. The more the adherence to the SGLT2i increased, the greater the decrease in FLI. Conclusions: SGLT2i showed a significant reduction in FLI and its components. We suggest that SGLT2i may have beneficial effects in reducing the prevalence of NAFLD in type 2 diabetes.

AB - Aims: This study was to determine the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes. Methods: We used data from the Korean National Health Insurance Service from 2014 to 2017. New drug users were screened, dipeptidyl peptidase 4 inhibitors (DPP4i) were set as the active comparator, and the differences between the two groups were corrected through propensity score matching. NAFLD was evaluated by the fatty liver index (FLI), which was calculated using body mass index, waist circumference, triglycerides, and gamma glutamyl peptidase. Results: After 1:1 matching, 25,371 patients in each group who received medication for an average of 299 days were analyzed. Despite similar baseline FLI of each group, the FLI of the SGLT2i users was 44.4 ± 26.7 and the FLI of the DPP4i users was 48.9 ± 27.3 (P value < 0.001) after treatment. SGLT2i showed more significant decrements than DPP4i in all components of FLI. The more the adherence to the SGLT2i increased, the greater the decrease in FLI. Conclusions: SGLT2i showed a significant reduction in FLI and its components. We suggest that SGLT2i may have beneficial effects in reducing the prevalence of NAFLD in type 2 diabetes.

KW - Dipeptidyl peptidase 4 inhibitors

KW - Nonalcoholic fatty liver disease

KW - Sodium-glucose cotransporter 2 inhibitors

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85143497021&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2022.110187

DO - 10.1016/j.diabres.2022.110187

M3 - Article

C2 - 36442545

AN - SCOPUS:85143497021

SN - 0168-8227

VL - 194

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

M1 - 110187

ER -

Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this